Precision Oncology Insights from COGC 2026: Key Strategies for Community Practices
At COGC 2026, expert Atlal Abusanad emphasized the importance of integrating molecular testing into clinical decision-making for effective precision oncology.
Precision oncology requires a systematic approach beyond just testing.
Community practices should start small and standardize processes.
Access to treatment and trials is essential for program success.
During the Community Oncology Global Congress (COGC 2026), Atlal Abusanad, a prominent figure in medical oncology from King Abdulaziz University, presented vital strategies for implementing precision oncology in community settings. He highlighted that successful precision oncology is not merely about conducting genomic tests but involves a comprehensive system that translates molecular data into actionable clinical decisions.
Abusanad pointed out that precision oncology often gets simplified to a sequence of ordering tests and interpreting results. However, the real challenge lies in effectively utilizing these results within the context of a patient's overall treatment plan. This includes determining the need for additional tests, identifying suitable therapies, and ensuring that patients can access these options. The emphasis is on creating a structured pathway where every step, from patient selection to treatment implementation, has a designated owner responsible for the process.
The presentation outlined five foundational pillars for a successful precision oncology program: governance, multidisciplinary expertise, standardized workflows, technology integration, and access. Governance ensures clear ownership of clinical and administrative responsibilities, while a diverse team of specialists is crucial for interpreting molecular findings and making informed decisions. Standardized workflows streamline the testing process, and technology plays a vital role in integrating molecular data into electronic health records, enhancing visibility and usability during patient care.
Abusanad stressed that access to recommended treatments and clinical trials is a core component of any precision oncology initiative. Without mechanisms for insurance coverage, financial assistance, and local trial access, even the most sophisticated testing can fail to benefit patients. He advocated for a gradual implementation strategy, suggesting that community practices start with one disease area, establish clear testing criteria, and expand as they refine their processes and measure outcomes.
Looking ahead, the focus for community oncology practices should be on developing reliable systems that convert molecular information into improved clinical decisions. By prioritizing integration and access, practices can enhance patient care and ensure that precision oncology becomes a standard part of cancer treatment pathways.
